Save Product
Product Details
Components
Cat. No.NameSizeFCN-H52W7Human FCGRT&B2M Heterodimer Protein50 μgFCA-H52H1Human CD64 Protein, His Tag50 μgCDA-H5221Human CD32a (R167) Protein, His Tag50 μgCD1-H5223Human CD32a (H167) Protein, His Tag50 μgCDB-H5228Human CD32b/c Protein, His Tag50 μgCD8-H52H4Human CD16a (V176) Protein, His Tag50 μgCDA-H5220Human CD16a (F176) Protein, His Tag50 μgCDB-H5227Human CD16b (NA1) Protein, His Tag50 μgCDB-H5222Human CD16b (NA2) Protein, His Tag50 μgKey parameter
Purity (SDS PAGE)> 95%Purity (MALS)90%Features
Comprehensive FcRs Protein Panel – No separate purchasing needed
High Purity – >95% by SDS-PAGE; >90% by SEC-MALS
Robust Stability – High batch-to-batch consistency
Full Data Package – SPR, BLI, and ELISA activity data includedFormulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-SPR
Captured Human FCGRT&B2M Heterodimer Protein, His Tag (Cat. No. FCN-H52W7) on CM5 Chip via Anti-His antibody can bind Herceptin® (Trastuzumab) with an affinity constant of 0.516 μM as determined in a SPR assay (Biacore T200) (QC tested).
Protocol
Human CD64, His Tag (Cat. No. FCA-H52H1) captured on CM5 chip via anti-His antibody can bind Herceptin® with an affinity constant of 4.92 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Protocol
Rituximab biosimilar (Cat. No. CD0-M36) captured on Protein A Chip can bind Human CD32a (R167), His Tag (Cat. No. CDA-H5221) with an affinity constant of 1.05 μM as determined in a SPR assay (Biacore 8K) (QC tested).
Protocol
Immobilized Human CD32a (H167), His Tag (SPR & BLI verified) (Cat. No. CD1-H5223) on CM5 Chip via anti-His antibody, can bind Rituximab with an affinity constant of 1.45 μM as determined in a SPR assay (Biacore T200) (QC tested).
Protocol
Immobilized Human CD32b/c, His Tag (Cat. No. CDB-H5228) on CM5 Chip via anti-His antibody, can bind Rituximab with an affinity constant of 15.1 μM as determined in a SPR assay (Biacore T200) (QC tested).
Protocol
Immobilized Human CD16a (V176), His Tag (Cat. No. CD8-H52H4) on CM5 Chip via anti-His antibody, can bind Herceptin with an affinity constant of 0.463 μM as determined in SPR assay (Biacore T200) (QC tested).
Protocol
Human CD16a (F176), His Tag (Cat. No. CDA-H5220) captured on CM5 chip via anti-His antibody can bind Rituximab biosimilar (Cat. No. CD0-M36) with an affinity constant of 1.18 µM as determined in a SPR assay (Biacore 8K) (QC tested).
Protocol
Immobilized Human CD16b (NA1), His Tag (Cat. No. CDB-H5227) on CM5 Chip via anti-His antibody, can bind Rituximab with an affinity constant of 8.17 μM as determined in a SPR assay (Biacore T200) (QC tested).
Protocol
Immobilized Human CD16b (NA2), His Tag (Cat. No. CDB-H5222) on CM5 Chip via anti-His antibody, can bind Rituximab with an affinity constant of 2.88 μM as determined in a SPR assay (Biacore T200) (QC tested).
Protocol
Customer Reviews Writing Reviews
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
